IMMUNOTHERAPY

This study tests whether adding immunotherapy to a special type of radiation (that spares key immune nodes) plus chemotherapy can help adults with advanced esophageal cancer live longer without the disease getting worse. About 432 participants will receive either the full combo o…

This study tests whether giving immunotherapy before surgery can help completely remove T4 colon cancer in people whose tumors have a specific DNA repair problem (dMMR). About 18 adults aged 18-75 with newly diagnosed, non-spread colon cancer will receive immunotherapy first, the…

This study tests whether adding a drug called narlumosbart and precise radiation (SBRT) to standard first-line chemotherapy and immunotherapy can help people with advanced non-small cell lung cancer that has spread to their bones. The goal is to improve how well the cancer respon…

This study tests a new treatment plan for people with advanced liver cancer that has spread to the main blood vessel or to a few other spots in the body. The treatment combines chemotherapy directly into the liver, two immunotherapy drugs, a targeted therapy, and precise radiatio…

This study tests a new treatment called RAK cell therapy, made from human umbilical cord blood, for people with advanced stomach cancer that has spread or come back after standard treatment. The goal is to see if it is safe and helps patients live longer without their cancer grow…

This study tests whether adding a probiotic called Probio-M9 to standard chemoradiation and immunotherapy can help shrink tumors more effectively in people with locally advanced rectal cancer. About 50 adults with stage II or III rectal cancer will be randomly assigned to receive…

This study tests whether adding an immunotherapy drug (PD-1 inhibitor) to a standard treatment plan (short-course radiation, chemotherapy, and a targeted therapy) can improve outcomes for people with locally advanced rectal cancer. About 104 adults with a specific type of rectal …

This study tests whether a combination of three drugs—weekly paclitaxel (or nab-paclitaxel), pembrolizumab, and mirabegron—can shrink tumors in adults whose ovarian cancer has returned. About 20 participants will receive the drugs and visit the clinic every two months for checkup…

This study aims to find the best treatment before surgery for people with esophageal or stomach cancer. It compares chemotherapy, chemoradiation, targeted therapy, and immunotherapy. The goal is to improve survival and reduce side effects. About 2000 adults with stage I to IVa ca…

This study tests whether adding radiotherapy to a drug combination (fruquintinib and sintilimab) can help control colorectal cancer that has spread to the liver and hasn't responded to two prior treatments. About 62 adults with a specific cancer subtype (MSS/pMMR) will be randoml…

This study tests whether a urine DNA test can help doctors decide how long to give immunotherapy for a severe type of bladder cancer that can't be fully removed with surgery. About 53 adults with very-high-risk non-muscle-invasive bladder cancer will receive immunotherapy, and th…

This study tests a new experimental drug (ABT-301) combined with two existing cancer treatments (tislelizumab and bevacizumab) in people with a specific type of advanced colorectal cancer that has not responded to at least two prior therapies. The goal is to find the safest and m…

This study tests whether a short course of radiation combined with immunotherapy and chemotherapy can shrink advanced gastroesophageal junction cancer enough to allow surgery. About 88 adults with locally advanced or unresectable disease will participate. The goal is to improve t…

This study tests whether adding low-dose radiation to standard targeted therapy and immunotherapy before surgery helps shrink head and neck tumors more effectively than the drugs alone. About 98 adults with operable head and neck squamous cell carcinoma will be randomly assigned …

This study tests a combination of four drugs (iparomlimab, tuvonralimab, apatinib, and irinotecan) in 39 adults with advanced AFP-producing stomach or gastroesophageal junction cancer that worsened after initial PD-1 inhibitor plus chemotherapy. The goal is to see if this new mix…

This study tests whether adding immunotherapy (a PD-1 inhibitor) after standard chemotherapy and radiation can help control advanced esophageal cancer for longer. About 452 adults with a specific type of esophageal cancer will receive either immunotherapy or monitoring after init…

This study tests whether adding immunotherapy to standard treatment (radiation and chemotherapy before surgery) can improve outcomes for people with locally advanced rectal cancer. It also compares a shorter course of radiation to a longer one. About 444 adults aged 18-75 with a …

This study tests whether adding an oral probiotic (Biolosion) to standard chemotherapy before surgery helps more women with early-stage triple-negative breast cancer achieve a complete response. About 192 participants will be randomly assigned to receive either standard therapy a…

This study tests whether adding radiation to a mix of chemotherapy and two immunotherapy drugs before surgery can improve outcomes for people with resectable stomach or gastroesophageal junction cancer. About 40 adults with HER2-negative disease will be randomly assigned to recei…

This study aims to find the best treatment plan for people with esophageal or esophagogastric junction cancer that cannot be removed by surgery. It will test adding immunotherapy (PD-1/PD-L1 antibodies) or targeted drugs to the standard chemoradiotherapy. About 2000 adults with s…

This study tests if taking oral sorbitol (a common sugar alcohol) can make standard chemotherapy and immunotherapy work better for people with locally advanced stomach cancer. About 80 adults will receive either sorbitol or a placebo alongside their cancer treatment. The goal is …

This study tests a two-step immunotherapy approach for people with B-cell acute lymphoblastic leukemia (B-ALL) who are older, too frail for standard chemo, or whose cancer has returned. Participants will receive two targeted drugs in sequence: blinatumomab and inotuzumab ozogamic…

This early-stage study tests an experimental drug called VSV-02 in 6 adults with advanced solid tumors (like melanoma, breast, or lung cancer) who have run out of standard treatments. The drug is given both into a vein and directly into the tumor to see if it can shrink or contro…

This study tests whether adding a natural supplement (β-hydroxybutyrate) to a standard treatment plan can help shrink or eliminate rectal cancer before surgery. The plan includes short-course radiation, immunotherapy, and chemotherapy. The goal is to see if more patients achieve …

This study looks at whether Reiki, a non-invasive therapy where a practitioner lightly places hands near the body, can help adults with cancer who feel very tired from immunotherapy. Twelve participants will either receive six weekly Reiki sessions or wait, then switch. Researche…

This study looks at whether a special intermittent fasting diet can help people with advanced lung cancer who are receiving immunotherapy. Researchers want to see if the diet is safe and if it can make the cancer treatment work better. About 66 patients will take part, following …

This study looks at how immunotherapy for advanced cancer changes a person's physical fitness and quality of life. About 67 adults with solid tumors will take fitness tests and answer questionnaires before starting treatment and again 12 weeks later. Researchers will also track l…

This study collects tumor samples from 2,000 people with various cancers to learn how to predict who will respond to immunotherapy. Participants donate tissue during a routine biopsy. The goal is to understand tumor biology and improve future treatment decisions, not to test a ne…

This study is developing a new, non-invasive way to monitor lung cancer patients after surgery using blood tests and artificial intelligence. Researchers will analyze blood samples from 100 patients who have had surgery and chemotherapy to look for signs of cancer returning. The …

This study follows 200 adults with advanced cancer who are receiving immunotherapy. Researchers want to understand their physical and emotional distress, financial burden, and care needs over one year. The goal is to create a tool that can predict who is at high risk for severe s…

This study looks at whether a patient's emotional state—like depression or anxiety—can influence how well advanced liver cancer responds to a combination of chemotherapy, targeted therapy, and immunotherapy. Researchers will follow 90 adults with BCLC stage B or C liver cancer, g…

This study is gathering detailed information from 500 people with small cell lung cancer to learn how to personalize their treatment. Researchers will track how well different combinations of radiation and immunotherapy work, and how they affect side effects. The goal is to find …

This study looks at small molecules called microRNA and tumor cells floating in the blood of 300 cancer patients before and after they receive immunotherapy. The goal is to see how these markers change with treatment. No new treatment is given; the study only observes and measure…

This study looks at whether a simple blood test can help doctors predict how well immunotherapy will work for people with head and neck cancer. Researchers will measure certain markers on tumor cells found in the blood and compare them to standard tissue tests. The goal is to mak…

This study looks at people who finished venom immunotherapy for Jack Jumper ant allergy 1.5 to 5 years ago. Participants will get a supervised sting and blood test to see if they are still protected. The goal is to learn how long the treatment works and how it affects quality of …

This study watches 500 lung cancer patients who received immunotherapy before any other treatment. Researchers want to see if removing the whole lung or just part of it leads to better outcomes, and whether surgery is better than other treatments like radiation. The goal is to le…